Cancer Research and Treatment

Cancer Research and Treatment Search

> Browse Articles > Search

Lung and Thoracic cancer

Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer

Jang Ho Lee, Eun Young Kim, Cheol-Kyu Park, Shin Yup Lee, Min ki Lee, Seong-Hoon Yoon, Jeong Eun Lee, Sang Hoon Lee, Seung Joon Kim, Sung Yong Lee, Jun Hyeok Lim, Tae-Won Jang, Seung Hun Jang, Kye Young Lee, Seung Hyeun Lee, Sei Hoon Yang, Dong Won Park, Chan Kwon Park, Hye Seon Kang, Chang Dong Yeo, Chang-Min Choi, Jae Cheol Lee

Cancer Res Treat. 2023;55(1):112-122. Published online July 19, 2022 DOI: https://doi.org/10.4143/crt.2022.381

Web of Science 3 Crossref 1

Assessment of Anti-tumor Efficacy of Osimertinib in Non-Small Cell Lung Cancer Patients by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma, or Pleural Effusion

Yeon Joo Kim, Won Jun Ji, Jae-Cheol Lee, Sung-Min Chun, Chang-Min Choi

Cancer Res Treat. 2022;54(4):985-995. Published online January 17, 2022 DOI: https://doi.org/10.4143/crt.2021.857

Web of Science 2 Crossref 2

Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer

Chaelin Lee, Miso Kim, Dong-Wan Kim, Tae Min Kim, Soyeon Kim, Sun-Wha Im, Yoon Kyung Jeon, Bhumsuk Keam, Ja-Lok Ku, Dae Seog Heo

Cancer Res Treat. 2022;54(1):140-149. Published online May 3, 2021 DOI: https://doi.org/10.4143/crt.2021.385

Web of Science 3 Crossref 4

A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2

Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim

Cancer Res Treat. 2019;51(2):777-787. Published online September 7, 2018 DOI: https://doi.org/10.4143/crt.2018.387

Web of Science 40 Crossref 36

The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma

Yen-Hsiang Huang, Kuo-Hsuan Hsu, Jeng-Sen Tseng, Kun-Chieh Chen, Chia-Hung Hsu, Kang-Yi Su, Jeremy J. W. Chen, Huei-Wen Chen, Sung-Liang Yu, Tsung-Ying Yang, Gee-Chen Chang

Cancer Res Treat. 2018;50(4):1294-1303. Published online January 4, 2018 DOI: https://doi.org/10.4143/crt.2017.512

Web of Science 46 Crossref 43

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors

Ji-Youn Han, Ki Hyeong Lee, Sang-We Kim, Young Joo Min, Eunkyung Cho, Youngjoo Lee, Soo-Hyun Lee, Hyae Young Kim, Geon Kook Lee, Byung Ho Nam, Hyesun Han, Jina Jung, Jin Soo Lee

Cancer Res Treat. 2017;49(1):10-19. Published online May 3, 2016 DOI: https://doi.org/10.4143/crt.2016.058

Web of Science 35 Crossref 33

Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410 FAX: +82-2-792-1410 E-mail: journal@cancer.or.kr

About | Browse Articles | Current Issue | For Authors and Reviewers